Abstract

There is a growing body of evidence which suggests that intestinal microbiota, especially Fusobacterium nucleatum (F. nucleatum), are associated with intestinal immune disease such as ulcerative colitis (UC). The mechanism by which F. nucleatum promotes intestinal epithelial cell (IEC) death remained undefined. Here, we investigated the potential mechanisms about how F. nucleatum aggravates IEC death in UC. We first detected the abundance of F. nucleatum in UC tissues and analyzed its relationship with the clinical characteristics of UC. Next, we explored whether F. nucleatum promotes intestinal epithelial cell death in vitro and in vivo. Furthermore, we extracted lipopolysaccharide (LPS) of the F. nucleatum and examined whether F. nucleatum exacerbates UC via LPS. Our results indicated that F. nucleatum was abundant in UC tissues and was correlated with clinical characteristics. In addition, we demonstrated that F. nucleatum and its LPS aggravated IEC death by promoted IEC autophagy. Furthermore, autophagy inhibitors, chloroquine (CQ), 3-methyladenine (3-MA) or Atg5 silencing prevented IEC death mediated by F. nucleatum, which suggests F. nucleatum may contribute to UC by activating autophagic cell death. All our results uncover a vital role of F. nucleatum in autophagic cell death and UC, giving rise to a new sight for UC therapy by inhibiting excessive IEC autophagy and autophagic cell death.

Highlights

  • Ulcerative colitis (UC) is a chronic, idiopathic, relapsing immunologic disorder of the gastrointestinal tract (Park et al, 2017)

  • Recent studies have found that F. nucleatum, a commensal within the oral cavity, is an emergent opportunistic pathogen of the gastrointestinal tract, having been abundantly found in patients suffering from ulcerative colitis (UC) (Nishida et al, 2018; Dinakaran et al, 2019)

  • We confirmed that F. nucleatum is an opportunistic risk factor of UC, which is closely related to the clinical characteristics of UC

Read more

Summary

Introduction

Ulcerative colitis (UC) is a chronic, idiopathic, relapsing immunologic disorder of the gastrointestinal tract (Park et al, 2017). UC is considered a worldwide healthcare issue, with its steady increase in prevalence (Jeong et al, 2019). The incidence and prevalence of UC have a dramatic rise in Asia, which makes it get more attention (Hou et al, 2009). The current treatment strategy of UC is mainly to use anti-inflammatory drugs, immunosuppressive agents, steroids and biological agents to control disease activity. It is essential to deepen the understanding of the pathogenesis in UC for further treatment.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call